The Infectious Disease Clinical Research Unit at Washington University School of Medicine has launched the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial, which will be conducted by the AIDS Clinical Trials Group. The school’s Infectious Disease Clinical Research Unit is one of 25 initial sites conducting ACTIV-2, which includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial. There is currently no approved vaccine or therapeutic to prevent or treat COVID-19. For information about enrolling in the trial at Washington University, please email email@example.com or call 314-454-0058.
Novel clinical trial launched to test multiple therapeutics to treat COVID-19